Benjamin Daniel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3676465/publications.pdf

Version: 2024-02-01

1651377 1336881 14 557 12 6 citations h-index g-index papers 35 35 35 645 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Treatment modalities for pityriasis rubra pilaris subtypes: a review. Journal of Dermatological Treatment, 2022, 33, 587-588.	1.1	6
2	Systemic pyoderma gangrenosum resulting in splenectomy: a cautionary case. Internal Medicine Journal, 2022, 52, 1097-1098.	0.5	0
3	A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB). JAAD International, 2021, 2, 134-152.	1.1	7
4	Impact of COVIDâ€19 on inpatient dermatology consults in an Australian tertiary hospital. Australasian Journal of Dermatology, 2021, 62, 427-428.	0.4	4
5	Pityriasis rubra pilaris treatment options: A retrospective case series from a tertiary hospital. Dermatologic Therapy, 2021, 34, e15128.	0.8	2
6	Flare of palmoplantar psoriasis with ustekinumab. Australasian Journal of Dermatology, 2020, 61, 63-65.	0.4	0
7	Mycobacterium chelonae infection mimicking Demodex folliculitis. Clinical and Experimental Dermatology, 2020, 45, 469-470.	0.6	0
8	Review of autoimmune blistering diseases: the Pemphigoid diseases. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1685-1694.	1.3	56
9	Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). Journal of the American Academy of Dermatology, 2014, 70, 89-97.e13.	0.6	57
10	Bullous pemphigoid: therapeutic algorithm and practical management. Expert Opinion on Orphan Drugs, 2013, 1, 405-412.	0.5	1
11	The development and validation of the Treatment of Autoimmune Bullous Disease Quality of Life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease. British Journal of Dermatology, 2013, 169, 1000-1006.	1.4	54
12	Development of a Quality-of-Life Instrument for Autoimmune Bullous Disease. JAMA Dermatology, 2013, 149, 1186.	2.0	70
13	Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts. Journal of the American Academy of Dermatology, 2012, 66, 479-485.	0.6	294
14	The Autoimmune Blistering Diseases in Australia: Status and Services. Dermatologic Clinics, 2011, 29, 687-690.	1.0	4